

# Australian outlook

## Sydney outbreak to drive a sharper slowdown

Free to View  
Economics - Australia

- ◆ Our forecasts already incorporated a marked slowdown in growth, from the recent rapid growth rates, in 2H21 and 2022
- ◆ We now expect the Sydney outbreak to see growth stall in 2H21, before picking up in 2022 as vaccination rates rise
- ◆ We lower our GDP growth forecasts for 2021 to 4.5% (from 5.1%) and for 2022 to 2.4% (from 2.8%)

---

**Paul Bloxham**  
Chief Economist, Australia, New Zealand & Global  
Commodities  
HSBC Bank Australia Limited

**Jamie Culling**  
Economist, Australia, NZ & Global Commodities  
HSBC Bank Australia Limited

---

## Another outbreak... and Delta could be different

An outbreak of the Delta variant has put Greater Sydney into lockdown from 26 June. The latest guidance from the authorities suggest it will be 'at least' five weeks in total, but the risk is that it is longer. As a point of comparison, the lockdown in Victoria in 2H20, which was more stringent and dealing with a less transmissible strain of the virus, was in place for 16 weeks, in order to drive the case numbers back to zero.

NSW Treasury estimates that every week of lockdown reduces GDP by AUD850m. On these estimates a six-week lockdown would knock 0.25% off annual GDP (1.0% off quarterly), while a 16-week lockdown would knock 0.7% off annual GDP. There is some risk that the lockdown will not get the case numbers back to zero, given the rapid transmission of the Delta variant. In this case, Sydney could be in some form of lockdown until vaccination rates are near herd immunity levels, which is unlikely until March 2022, at the earliest.

Other states have mostly closed their borders to Greater Sydney, and there has been some early spread of the outbreak to Victoria, which has seen that state announce a 5-day lockdown from 16 July. There are a small number of cases in Queensland but the remaining states and territories have no community transmissions at this stage.

Policymakers have delivered fiscal support measures for affected households and businesses, but on a smaller scale than the large earlier COVID-19 fiscal programmes.

Even before the Sydney outbreak we had expected Australia's growth to slow from its recent rapid growth rates, as population growth has stalled due to the closed border and as the fiscal impulse fades. After growth averaged 2.8% q-o-q a quarter in the three quarters to 1Q21, we had forecast it to slow to 0.6-0.7% q-o-q a quarter.

We now assume the Greater Sydney lockdown will see q-o-q GDP contract by -0.3% in 3Q21 and rise by only 0.3% in 4Q21, before bouncing back in 2022. The other headwinds to growth in 2022, including the only slowly re-opening border and tensions with China, are expected to remain.

*This is an abridged version of a report of the same title published on 16 July 2021. Please contact your HSBC representative or email [AskResearch@hsbc.com](mailto:AskResearch@hsbc.com) for more information.*


## Disclosures & Disclaimer

This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it.


Issuer of report: HSBC Bank Australia Limited

View HSBC Global Research at:  
<https://www.research.hsbc.com>

## 1. COVID-19 cases in NSW have been increasing rapidly...



## 2. ...with the 'Delta' variant moving faster than NSW lockdown restrictions



## The COVID-19 'Delta' variant...

The COVID-19 virus has undergone mutations since the initial stages of the pandemic Australia grappled with last year. The current 'Delta' strain is more contagious than the original, with the WHO calling it "the fastest and fittest" – The Delta variant is spreading 50% faster than the Alpha, variant, which was 50% more contagious than the original strain of SARS-CoV-2. It is estimated that the average person infected with the original coronavirus strain will infect 2.5 other people, while the Delta variant would spread from one person to 3.5 or 4 other people (*Yale Medicine*, 2021). While Australia's closed international border, hotel quarantine system, contact tracing, and lockdown measures worked well in the face of the original pandemic, the Delta variant presents a greater challenge.

**The Delta variant is different and may be much harder to eliminate**

## ...is spreading in the Greater Sydney region

The latest COVID-19 outbreak in Australia originated in Sydney's Bondi area on 17 June. Since then, NSW has recorded 925 cases (Chart 1, as at 14 July). Australia has recorded a total of 1,140 cases over the same period, with an emerging linked cluster in Victoria.

**The outbreak in Greater Sydney has led to a lockdown**

The main concern for authorities is the number of unlinked COVID-19 cases (that is, those with an unidentified source of transmission), and cases that have been in the community while infectious. Since the start of July, NSW has recorded 186 unlinked COVID-19 cases, and 198 cases who were infectious while in the community.

To combat the spread, the NSW government has implemented lockdown measures. These measures are similar to ones implemented at the peak of the pandemic in 2020, and those in Melbourne's outbreaks (Chart 2). According to Google mobility data, mobility has been limited similar to Victoria's previous lockdowns. The restrictions include stay at home rules, where a citizen can only leave their home for 'essential' reasons, such as food, exercise, and essential work.

## Australia's vaccine rollout is now front and centre...

A key challenge is that Australia has had a slow COVID-19 vaccine rollout, by global standards. Only around 10% of the population has been fully vaccinated. The current bulk of the vaccine supply is also the AstraZeneca vaccine, making up around 77% of the weekly vaccine doses available (2.2m doses per week in July). The government has emphasised the Pfizer vaccine is preferred for under 60 year olds, but at 22% of available doses (650k) supply is still limited.

**The vaccine rollout has been slow in Australia**

Pfizer is due to ramp up to 930k doses per week in September (49%), and 1.7m doses per week from October (80%).


HSBC's expectation is that herd immunity will not be reached until 1Q22 (Chart 3).

**We forecast herd immunity of around 70% coverage will not be reached until March 2022**


Our projections assume that vaccine rollout increases from its June pace of around 0.18% of the population fully vaccinated each day, to 0.3% of the population, which is more in line with the increased pace of initial vaccinations underway. From October, we factor in some slowdown in pace by applying the trend seen in the United States for the vaccine rollout once it hits around 50% of the population. There is large uncertainty here, with a downside risk of slow vaccine supply, but an upside risk of a renewed push from the government for citizens to get vaccinated.

Given the vaccine delivery timeline and current pace, there is a risk that Sydney could see some form of lockdown maintained until herd immunity is reached.

### 3. Herd immunity is projected to be reached in 1Q22



### 4. The current outbreak means we lower our GDP forecast



## ...with a hit to GDP growth in 2H21

NSW Treasury estimates that every week of lockdown reduces GDP by AUD850m. With Australia's annual GDP currently around AUD1931bn, each week of lockdown would reduce annual GDP by 0.04%. A six-week lockdown would reduce annual GDP by 0.25%, or, over 3Q21, a 1% reduction in quarterly GDP. These same estimates would suggest a 16-week lockdown, therefore, would be 0.7% off annual GDP, or 2.8% off in the quarter. Of course, there is considerable uncertainty with estimates such as these and a risk that a longer lockdown does more permanent damage, such as through increased business failures.

**We see GDP contracting in 3Q21 as a result of the Sydney outbreak**

Using these estimates as a guide, we lower our GDP forecasts. After growth averaged 2.8% q-o-q a quarter in the three quarters to 1Q21, we had expected it to slow to 0.6-0.7% q-o-q a quarter. Now, we are now assuming the Greater Sydney lockdown will see q-o-q GDP contract by -0.3% in 3Q21 and rise by only 0.3% in 4Q21, before bouncing back in 2022. Essentially, we expect this reduction to come through household consumption, particularly in services.

The labour market is also likely to be negatively affected over 3Q21. Around 22% of national employment is in Sydney, and employment is likely to reduce while the lockdown persists. The fiscal support (outlined below) should help keep some people in jobs, but not to the same extent as 'JobKeeper'. We expect the unemployment rate to rise in 3Q21, after having fallen in recent quarters. Although the fall in employment would typically lead to an even higher unemployment rate, we assume that the participation rate declines temporarily as workers would be unable to look for new jobs during the lockdown.

## Fiscal support package

In response to the outbreak and lockdown, both the NSW State government and Federal government have announced various support packages for businesses and individuals. The Commonwealth and NSW government will split the cost of the support package equally. The targeted fiscal support does offer some support to 3Q21 GDP, but we expect the effects of the lockdown to still be felt. The fiscal package includes:

### Payments to individuals

AUD600 per week will be provided for individuals losing more than 20 hours of employment per week, increased slightly from the AUD500 per week provided in Melbourne in May and June, and for the first three weeks of the Sydney lockdown.

AUD375 per week will also be provided for individuals who lose 8 to 20 hours per week, up from AUD325 per week provided in Melbourne and the first three weeks of Sydney lockdown, with the liquid assets test (previously you were unable to get the payments if you had enough liquid assets) being removed.

Compared to the government's ongoing 'JobSeeker' support, this financial assistance is almost double. Compared to the government's 'JobKeeper' programme, the payments are relatively similar, with 'JobKeeper' offering AUD600 per week for employees who work more than 20 hours, and AUD375 per week for employees who work less than 20 hours (although this dropped to AUD500 and AUD325, respectively, from January 2021 until the programme ended in March 2021).

### Support for businesses

A maximum of AUD10,000 per week will be provided to businesses, with turnover between AUD75k and AUD50m, suffering a 30% decline in annual turnover (relative to pre-pandemic), on the condition that no employees are laid off.

Sole traders will be eligible for AUD1,000 per week.

## RBA to remain dovish

We have long been of the view that the RBA will remain dovish as it faces a significant challenge getting inflation back to target.

We maintain our view that the RBA will keep its cash rate steady at 0.10% in 2021 and 2022, and maintain its 0.10% target on April 2024 three-year bonds. We expect the QE programme to continue beyond September. The RBA announced in early July that it was set to taper its bond purchases from AUD5bn a week to AUD4bn a week from late September. The sharper-than-expected slowdown in growth, as a result of the Greater Sydney outbreak, raises the risk that the RBA decides not to taper after all.

---

Fiscal support has been announced, but it is smaller in scale than the earlier programmes

---

We see the RBA remaining dovish

# Disclosure appendix

## Analyst Certification

The following analyst(s), economist(s), or strategist(s) who is(are) primarily responsible for this report, including any analyst(s) whose name(s) appear(s) as author of an individual section or sections of the report and any analyst(s) named as the covering analyst(s) of a subsidiary company in a sum-of-the-parts valuation certifies(y) that the opinion(s) on the subject security(ies) or issuer(s), any views or forecasts expressed in the section(s) of which such individual(s) is(are) named as author(s), and any other views or forecasts expressed herein, including any views expressed on the back page of the research report, accurately reflect their personal view(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: Paul Bloxham and Jamie Culling

## Important disclosures

This document has been prepared and is being distributed by the Research Department of HSBC and is not for publication to other persons, whether through the press or by other means.

This document is for information purposes only and it should not be regarded as an offer to sell or as a solicitation of an offer to buy the securities or other investment products mentioned in it and/or to participate in any trading strategy. Advice in this document is general and should not be construed as personal advice, given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. If necessary, seek professional investment and tax advice.

Certain investment products mentioned in this document may not be eligible for sale in some states or countries, and they may not be suitable for all types of investors. Investors should consult with their HSBC representative regarding the suitability of the investment products mentioned in this document and take into account their specific investment objectives, financial situation or particular needs before making a commitment to purchase investment products.

The value of and the income produced by the investment products mentioned in this document may fluctuate, so that an investor may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Value and income from investment products may be adversely affected by exchange rates, interest rates, or other factors. Past performance of a particular investment product is not indicative of future results.

HSBC and its affiliates will from time to time sell to and buy from customers the securities/instruments, both equity and debt (including derivatives) of companies covered in HSBC Research on a principal or agency basis or act as a market maker or liquidity provider in the securities/instruments mentioned in this report.

Analysts, economists, and strategists are paid in part by reference to the profitability of HSBC which includes investment banking, sales & trading, and principal trading revenues.

Whether, or in what time frame, an update of this analysis will be published is not determined in advance.

For disclosures in respect of any company mentioned in this report, please see the most recently published report on that company available at [www.hsbcnet.com/research](http://www.hsbcnet.com/research). HSBC Private Banking clients should contact their Relationship Manager for queries regarding other research reports. In order to find out more about the proprietary models used to produce this report, please contact the authoring analyst.

**Additional disclosures**

- 1 This report is dated as at 16 July 2021.
- 2 All market data included in this report are dated as at close 15 July 2021, unless a different date and/or a specific time of day is indicated in the report.
- 3 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Information Barrier procedures are in place between the Investment Banking, Principal Trading, and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.
- 4 You are not permitted to use, for reference, any data in this document for the purpose of (i) determining the interest payable, or other sums due, under loan agreements or under other financial contracts or instruments, (ii) determining the price at which a financial instrument may be bought or sold or traded or redeemed, or the value of a financial instrument, and/or (iii) measuring the performance of a financial instrument or of an investment fund.

# Disclaimer

## Legal entities as at 1 December 2020

'UAE' HSBC Bank Middle East Limited, DIFC; HSBC Bank Middle East Limited, Dubai; 'HK' The Hongkong and Shanghai Banking Corporation Limited, Hong Kong; 'TW' HSBC Securities (Taiwan) Corporation Limited; 'CA' HSBC Securities (Canada) Inc.; 'France' HSBC Continental Europe; 'Spain' HSBC Continental Europe, Sucursal en España; 'Italy' HSBC Continental Europe, Italy; 'Sweden' HSBC Continental Europe Bank, Sweden Filial; 'DE' HSBC Trinkaus & Burkhardt AG, Düsseldorf; '000' HSBC Bank (RR), Moscow; 'IN' HSBC Securities and Capital Markets (India) Private Limited, Mumbai; 'JP' HSBC Securities (Japan) Limited, Tokyo; 'EG' HSBC Securities Egypt SAE, Cairo; 'CN' HSBC Investment Bank Asia Limited, Beijing Representative Office; The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Branch; HSBC Securities (South Africa) (Pty) Ltd, Johannesburg; HSBC Bank plc, London, Tel Aviv; 'US' HSBC Securities (USA) Inc, New York; HSBC Yatirim Menkul Degerler AS, Istanbul; HSBC México, SA, Institución de Banca Múltiple, Grupo Financiero HSBC; HSBC Bank Australia Limited; HSBC Bank Argentina SA; HSBC Saudi Arabia Limited; The Hongkong and Shanghai Banking Corporation Limited, New Zealand Branch incorporated in Hong Kong SAR; The Hongkong and Shanghai Banking Corporation Limited, Bangkok Branch; PT Bank HSBC Indonesia; HSBC Qianhai Securities Limited; Banco HSBC S.A.

## Issuer of report

**HSBC Bank Australia Limited**  
 Level 38  
 Tower 1, International Towers Sydney  
 100 Barangaroo Avenue  
 Sydney NSW 2000  
 Australia  
 Telephone: +61 2 9006 5888  
 Fax: +61 2 9255 2205  
 Website: [www.research.hsbc.com](http://www.research.hsbc.com)

In Australia, this publication has been distributed by The Hongkong and Shanghai Banking Corporation Limited (ABN 65 117 925 970, AFSL 301737) for the general information of its "wholesale" customers (as defined in the Corporations Act 2001). Where distributed to retail customers, this research is distributed by HSBC Bank Australia Limited (ABN 48 006 434 162 AFSL No. 232595). These respective entities make no representations as to the products or services mentioned in this document are available to persons in Australia or are necessarily suitable for any particular person or appropriate in accordance with local law. No consideration has been given to the particular investment objectives, financial situation or particular needs of any recipient. In the UK, this publication is distributed by HSBC Bank plc for the information of its Clients (as defined in the Rules of FCA) and those of its affiliates only. Nothing herein excludes or restricts any duty or liability to a customer which HSBC Bank plc has under the Financial Services and Markets Act 2000 or under the Rules of FCA and PRA. A recipient who chooses to deal with any person who is not a representative of HSBC Bank plc in the UK will not enjoy the protections afforded by the UK regulatory regime. HSBC Bank plc is regulated by the Financial Conduct Authority and the Prudential Regulation Authority. If this research is received by a customer of an affiliate of HSBC, its provision to the recipient is subject to the terms of business in place between the recipient and such affiliate. This publication is distributed in New Zealand by The Hongkong and Shanghai Banking Corporation Limited, New Zealand Branch incorporated in Hong Kong SAR. This material is distributed in Japan by HSBC Securities (Japan) Limited. HSBC Securities (USA) Inc. accepts responsibility for the content of this research report prepared by its non-US foreign affiliate. The information contained herein is under no circumstances to be construed as investment advice and is not tailored to the needs of the recipient. All US persons receiving and/or accessing this report and intending to effect transactions in any security discussed herein should do so with HSBC Securities (USA) Inc. in the United States and not with its non-US foreign affiliate, the issuer of this report. In Korea, this publication is distributed by either The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch ("HBAP SLS") or The Hongkong and Shanghai Banking Corporation Limited, Seoul Branch ("HBAP SEL") for the general information of professional investors specified in Article 9 of the Financial Investment Services and Capital Markets Act ("FSCMA"). This publication is not a prospectus as defined in the FSCMA. It may not be further distributed in whole or in part for any purpose. Both HBAP SLS and HBAP SEL are regulated by the Financial Services Commission and the Financial Supervisory Service of Korea. In Singapore, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch for the general information of institutional investors or other persons specified in Sections 274 and 304 of the Securities and Futures Act (Chapter 289) ("SFA") and accredited investors and other persons in accordance with the conditions specified in Sections 275 and 305 of the SFA. Only Economics or Currencies reports are intended for distribution to a person who is not an Accredited Investor, Expert Investor or Institutional Investor as defined in SFA. The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch accepts legal responsibility for the contents of reports pursuant to Regulation 32C(1)(d) of the Financial Advisers Regulations. This publication is not a prospectus as defined in the SFA. This publication is not a prospectus as defined in the SFA. It may not be further distributed in whole or in part for any purpose. The Hongkong and Shanghai Banking Corporation Limited Singapore Branch is regulated by the Monetary Authority of Singapore. Recipients in Singapore should contact a "Hongkong and Shanghai Banking Corporation Limited, Singapore Branch" representative in respect of any matters arising from, or in connection with this report. Please refer to The Hongkong and Shanghai Banking Corporation Limited Singapore Branch's website at [www.business.hsbc.com.sg](http://www.business.hsbc.com.sg) for contact details. HSBC México, S.A., Institución de Banca Múltiple, Grupo Financiero HSBC is authorized and regulated by Secretaría de Hacienda y Crédito Público and Comisión Nacional Bancaria y de Valores (CNBV).

In the European Economic Area, this publication has been distributed by HSBC Continental Europe or by such other HSBC affiliate from which the recipient receives relevant services.

In Canada, this document has been distributed by HSBC Securities (Canada) Inc. (member IIROC), and/or its affiliates. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed judgment upon these materials, the information contained herein or the merits of the securities described herein, and any representation to the contrary is an offense. In Brazil, this document has been distributed by Banco HSBC S.A. ("HSBC Brazil"), and/or its affiliates. As required by Instruction No. 598/18 of the Securities and Exchange Commission of Brazil (Comissão de Valores Mobiliários), potential conflicts of interest concerning (i) HSBC Brazil and/or its affiliates; and (ii) the analyst(s) responsible for authoring this report are stated on the chart above labelled "HSBC & Analyst Disclosures".

This material is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. This document has been prepared without taking account of the objectives, financial situation or needs of any specific person who may receive this document. Any such person should, before acting on the information in this document, consider the appropriateness of the information, having regard to the personal objectives, financial situation and needs. In all cases, anyone proposing to rely on or use the information in this document should independently verify and check its accuracy, completeness, reliability and suitability and should obtain independent and specific advice from appropriate professionals or experts. HSBC has based this document on information obtained from sources it believes to be reliable but which it has not independently verified; HSBC makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of HSBC only and are subject to change without notice. From time to time research analysts conduct site visits of covered issuers. HSBC policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits. HSBC and its affiliates and/or their officers, directors and employees may have positions in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). HSBC and its affiliates may act as market maker or have assumed an underwriting commitment in the securities of any companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform banking or underwriting services for or relating to those companies. This material may not be further distributed in whole or in part for any purpose. No consideration has been given to the particular investment objectives, financial situation or particular needs of any recipient. (070905)

If you are an HSBC Private Banking ("PB") customer with approval for receipt of relevant research publications by an applicable HSBC legal entity, you are eligible to receive this publication. To be eligible to receive such publications, you must have agreed to the applicable HSBC entity's terms and conditions for accessing research and the terms and conditions of any other internet banking service offered by that HSBC entity through which you will access research publications ("the Terms"). Distribution of this publication is the sole responsibility of the HSBC entity with whom you have agreed the Terms. If you do not meet the aforementioned eligibility requirements please disregard this publication and, if you are a customer of PB, please notify your Relationship Manager. Receipt of research publications is strictly subject to the Terms and any other conditions or disclaimers applicable to the provision of the publications that may be advised by PB.

© Copyright 2021, HSBC Bank Australia Ltd, ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of HSBC Bank Australia Limited. MCI (P) 028/02/2021, MCI (P) 087/10/2020

[1174552]